EB + GPN offer a fresh focus on industry data—exploring a specific aspect of the optometric practice with each issue. Here, GPN shares insights into polycarbonate lenses as a key lens opportunity for patients.
While these spectacle lenses are not yet approved by the US Food and Drug Administration, it’s likely a nod from the organization is not too far off. As a result, discussing the factors that influence treatment success makes sense.
Eyenovia's late-stage study for near-sightedness in children with an experimental drug-device combination has been discontinued after failing to slow myopia progression, leading to consideration of strategic alternatives.